The company received the US FDA’s 510(k) clearance for its human umbilical cord-derived Corplex P. The company had earlier launched an intact placental membrane allograft in 2016
The clearance was granted based on the results from the clinical study depicting the safety and effectiveness of Corplex P through testing, compliance with pre-market submission requirements
Corplex P is a medical device derived from the human umbilical cord extracellular matrix (ECM) approved and indicated for the management of acute and chronic wounds
Ref: StimLabs | Image: StimLabs
Related News:- SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
